½ÃÀ庸°í¼­
»óǰÄÚµå
1604751

¼¼°èÀÇ ÀÚµ¿ ÁÖ»ç±â ½ÃÀå : ÀûÀÀÁõº°, ¿ëµµº°, ÃÖÁ¾ »ç¿ëÀÚº° ¿¹Ãø(2025-2030³â)

Auto-disable Syringes Market by Indication (Infectious Diseases, Inflammatory/Auto-Immune Diseases), Application (Blood Collection, Drug Delivery, Vaccination), End-User - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 189 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

ÀÚµ¿ ÁÖ»ç±â ½ÃÀåÀº 2023³â¿¡ 232¾ï 8,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2024³â¿¡´Â 259¾ï 4,000¸¸ ´Þ·¯¿¡ µµ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 11.54%·Î ¼ºÀåÇÏ¿©, 2030³â¿¡´Â 500¾ï 1,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÀÚµ¿ ÁÖ»ç±â´Â Àç»ç¿ëÀ» ¹æÁöÇϵµ·Ï ¼³°èµÈ Ư¼ö ÀÇ·á±â±â·Î, ºÒ°áÇÑ ÁÖ»ç ¹Ù´Ã·Î °¨¿°ÀÌ ÆÛÁö´Â À§ÇèÀ» Å©°Ô ÁÙÀÏ ¼ö ÀÖ½À´Ï´Ù. ¼¼°èÀÇ ÀÇ·á ¾ÈÀü ±âÁØ¿¡ ÀûÇÕÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ÁÖ»ç±âÀÇ Çʿ伺Àº ƯÈ÷ HIV ¹× °£¿°°ú °°Àº °¨¿°ÀÌ ¸¸¿¬ÇÑ °³¹ß µµ»ó Áö¿ª¿¡¼­ ¾ÈÀüÇÑ ÁÖ»ç ½ÇõÀÇ Çʿ伺¿¡ ÀÇÇØ ÃÊ·¡µË´Ï´Ù. ¾à¹° Åõ¿©, º´¿ø ¹× Ŭ¸®´Ð¿¡¼­ ÀÇ»ç Ä¡·á °³ÀÔ¿¡ ³Î¸® ÀÀ¿ëµÇ°í ÀÖ½À´Ï´Ù. ÃÖÁ¾ ¿ëµµÀÇ ¹üÀ§´Â ÀÇ·á½Ã¼³, °øÁߺ¸°Ç±â±¸, ¿¹¹æÁ¢Á¾ Ä·ÆäÀÎ µî ¼¼°èÀûÀ¸·Î È®»êµÇ°í ÀÖ½À´Ï´Ù. Áß¿äÇÑ ¼ºÀå ¿äÀÎÀÔ´Ï´Ù. ¶ÇÇÑ ÇöÀç ÁøÇàÁßÀÎ COVID-19 ÆÒµ¥¹ÍÀº ¾ÈÀüÇϰí È¿À²ÀûÀÎ ¹é½Å Á¢Á¾ ¹æ¹ý¿¡ ´ëÇÑ ¼ö¿ä¸¦ ³ôÀ̰í ÀÖÀ¸¸ç ÀÚµ¿ Å»Âø½Ä ÁÖ»ç±â Á¦Á¶¾÷ü°¡ ½ÃÀåÀ» È®´ëÇÏ´Â ¸Å¿ì Áß¿äÇÑ ±âȸ°¡ µÇ°í ÀÖ½À´Ï´Ù. °­È­µÇ¾ú½À´Ï´Ù. ÀÌ·¯ÇÑ ÁÖ»ç±â´Â ¹é½Å Á¢Á¾ °ü¸®¸¦ À§ÇÑ µðÁöÅÐ ÃßÀû ½Ã½ºÅÛÀÇ ÅëÇÕ°ú ÀÚµ¿È­¸¦ ÅëÇÑ »ý»ê È¿À² Çâ»ó µî ±â¼ú Çõ½ÅÀÇ °¡´É¼ºÀ» Á¦°øÇÕ´Ï´Ù. Á¦Á¶ ºñ¿ëÀÇ ³ôÀÌ¿ÍÀÇ Àåºñ¿¡ ´ëÇÑ °Ç°­ °ü¸®ÀÇ º¸±Þ°ú Á¾»çÀÚ ±³À°ÀÇ Çʿ伺°ú °°Àº °úÁ¦°¡ ÀÖ½À´Ï´Ù. ±â¾÷ÀÌ Á¦Ç° Â÷º°È­¿Í ¾ö°ÝÇÑ º¸°Ç °¡À̵å¶óÀÎ Áؼö¿¡ ÁÖ·ÂÇϰí ÀÖ½À´Ï´Ù. ±â¾÷Àº ȯ°æ¿¡ ´ëÇÑ ¹è·Á¿¡¼­ »ýºÐÇØ¼º ¼ÒÀ縦 ¸ð»öÇÏ°í ºñ¿ë È¿À²ÀûÀÎ Á¦Á¶ ±â¼úÀ» °³¹ßÇÔÀ¸·Î½á ±â¼ú Çõ½ÅÀ» ¸ñÇ¥·Î ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â°ü ¹× NGO¿ÍÀÇ ÆÄÆ®³Ê½Ê È®´ë ƯÈ÷ ÃæºÐÇÑ ¼­ºñ½º¸¦ ¹ÞÁö ¸øÇÑ Áö¿ª¿¡¼­ ³Î¸® À¯Åë½ÃŰ´Â °Íµµ Àü·«Àû ±âȸ°¡ µË´Ï´Ù. È®´ë¿¡ ÁÖ·ÂÇØ¾ßÇÕ´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁسâ(2023) 232¾ï 8,000¸¸ ´Þ·¯
ÃßÁ¤³â(2024) 259¾ï 4,000¸¸ ´Þ·¯
¿¹Ãø³â(2030) 500¾ï 1,000¸¸ ´Þ·¯
º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR)(%) 11.54%

½ÃÀå ¿ªÇÐ : ºü¸£°Ô ÁøÈ­ÇÏ´Â ÀÚµ¿ ÁÖ»ç±â ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

ÀÚµ¿ÁÖ»ç±â ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ë¿¡ ÀÇÇØ º¯¸ð¸¦ ÀÌ·ç°í ÀÖ½À´Ï´Ù. ±×¸®°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ ¾ò±â À§ÇØ Áغñ µÉ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µ¿ÇâÀ» Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª¿¡ °ÉÄ£ ´Ù¾çÇÑ À§ÇèÀ» ÁÙÀÏ ¼ö ÀÖÀ¸¸ç, ¼ÒºñÀÚ Çൿ°ú ÀÌ´Â Á¦Á¶ ºñ¿ë°ú ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» ´õ¿í ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ¹Ù´Ã Â±â ¼Õ»ó°ú ±³Â÷ °¨¿°ÀÇ ¹ß»ý·üÀÇ »ó½Â
    • ÀÚµ¿ ÁÖ»ç±âÀÇ »ç¿ë¿¡ ´ëÇÑ ÇコÄɾî Á¶Á÷ÀÇ ´ëÆøÀûÀÎ ±âÈ£¼º
    • ¿¹¹æ Á¢Á¾¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • Á¶´Þ ºñ¿ë°ú ¿øÀç·á ºñ¿ëÀÇ »ó½Â
  • ½ÃÀå ±âȸ
    • ´ë±Ô¸ð Ä·ÆäÀο¡ÀÇ Àû¿ë ¹üÀ§ È®´ë
    • ÀÚµ¿ ÁÖ»ç±âÀÇ Áö¼ÓÀûÀÎ ¹ßÀü
  • ½ÃÀåÀÇ °úÁ¦
    • ¾ÈÀüÇÏÁö ¾ÊÀº ÁÖ»ç ¹æ¹ý¿¡ °üÇÑ ¿ì·Á¿Í ¹°·ù»óÀÇ °úÁ¦

Porter's Five Forces : ÀÚµ¿ ÁÖ»ç±â ½ÃÀåÀ» Ž»öÇÏ´Â Àü·« µµ±¸

Porter's Five Forces Framework´Â ½ÃÀå »óȲ°æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. Porter's Five Forces Framework´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ ޱ¸ÇÏ´Â ¸íÈ®ÇÑ ±â¼úÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÀλçÀÌÆ®À» ÅëÇØ ±â¾÷Àº ÀÚ»çÀÇ °­Á¡À» Ȱ¿ëÇϰí, ¾àÁ¡À» ÇØ°áÇϰí, ÀáÀçÀûÀÎ °úÁ¦¸¦ ÇÇÇÒ ¼ö ÀÖÀ¸¸ç, º¸´Ù °­ÀÎÇÑ ½ÃÀå¿¡¼­ÀÇ Æ÷Áö¼Å´×À» º¸ÀåÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : ÀÚµ¿ ÁÖ»ç±â ½ÃÀå¿¡¼­ ¿ÜºÎ ¿µÇâÀ» ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº ÀÚµ¿ ÁÖ»ç±â ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇϴµ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀÎ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù. PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀûÀÎ À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¾ÕÀ¸·Î ¿¹»óµÇ´Â Àû±ØÀûÀÎ ÀÇ»ç °áÁ¤À» ÇÒ Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® ÀÚµ¿ ÁÖ»ç±â ½ÃÀå °æÀï ±¸µµ ÆÄ¾Ç

ÀÚµ¿ ÁÖ»ç±â ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¼öÀÍ, °í°´ ±â¹Ý, ¼ºÀå·ü µî ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀï Æ÷Áö¼Å´×À» ¹àÈú ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®À» ÅëÇØ ½ÃÀå ÁýÁß, ´ÜÆíÈ­, ÅëÇÕ µ¿ÇâÀ» ¹àÇô³»°í °ø±Þ¾÷ü´Â °æÀïÀÌ Ä¡¿­ÇØÁö¸é¼­ ÀÚ»çÀÇ ÁöÀ§¸¦ ³ôÀÌ´Â Àü·«Àû ÀÇ»ç °áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ Áö½ÄÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º : ÀÚµ¿ ÁÖ»ç±â ½ÃÀå¿¡¼­ °ø±Þ¾÷üÀÇ ¼º´É Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â ÀÚµ¿ ÁÖ»ç±â ½ÃÀå¿¡¼­ º¥´õ¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ Çà·ÄÀ» ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº °ø±Þ¾÷üÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±âÁØÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ¸Â´Â ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç °áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù. ³× °¡Áö »çºÐ¸éÀ» ÅëÇØ °ø±Þ¾÷ü¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ¼¼ºÐÈ­ÇÏ¿© Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê ¹× ¼Ö·ç¼ÇÀ» ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù.

Àü·« ºÐ¼® ¹× Ãßõ ÀÚµ¿ ÁÖ»ç±â ½ÃÀå¿¡¼­ ¼º°øÀ» À§ÇÑ ±æÀ» ±×¸®±â

ÀÚµ¿ ÁÖ»ç±â ½ÃÀåÀÇ Àü·« ºÐ¼®Àº ½ÃÀå¿¡¼­ÀÇ ÇöÀå °­È­¸¦ ¸ñÇ¥·Î ÇÏ´Â ±â¾÷¿¡ ÇʼöÀûÀÎ ¿ä¼ÒÀÔ´Ï´Ù. ÀÌ Á¢±Ù¹ýÀ» ÅëÇØ °æÀï ±¸µµ¿¡¼­ °úÁ¦¸¦ ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö Àִ üÁ¦¸¦ ±¸ÃàÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀåÀÇ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõ : ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·Â Æò°¡.

2. ½ÃÀå °³Ã´µµ : ½ÅÈï ½ÃÀåÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇÏ°í ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡ÇÏ¸ç ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù¾çÈ­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä Áøº¸, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú Áøº¸ µîÀ» °ËÁõÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÃÖ÷´Ü ±â¼ú, R&D Ȱµ¿, Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

¶ÇÇÑ ÀÌÇØ°ü°èÀÚ°¡ ÃæºÐÇÑ Á¤º¸¸¦ ¾ò°í ÀÇ»ç°áÁ¤À» ÇÒ ¼ö ÀÖµµ·Ï Áß¿äÇÑ Áú¹®¿¡ ´ë´äÇϰí ÀÖ½À´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå ¿¹ÃøÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹® ¹× Áö¿ªÀº ¾îµðÀԴϱî?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5. º¥´õ ½ÃÀå ÁøÀÔ, ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
      • ħħ »ç°í¿Í ±³Â÷ °¨¿°ÀÇ ¹ß»ý·ü »ó½Â
      • ÀÇ·á±â°üÀº ÀÚµ¿ ÁÖ»ç±âÀÇ »ç¿ëÀ» °­ÇÏ°Ô ÁÁ¾ÆÇϰí ÀÖ´Ù
      • ¿¹¹æÁ¢Á¾ ¼ö¿ä Áõ°¡
    • ¾ïÁ¦¿äÀÎ
      • Á¶´Þ ºñ¿ë°ú ¿øÀç·áºñ°¡ ³ô´Ù
    • ±âȸ
      • ´ë·® ½Åû Ä·ÆäÀÎÀÇ ¹üÀ§ È®´ë
      • ÀÚµ¿ ÁÖ»ç±âÀÇ Áö¼ÓÀûÀÎ Áøº¸
    • °úÁ¦
      • ¾ÈÀüÇÏÁö ¾ÊÀº ÁÖ»ç¹æ¹ý°ú ¹°·ù»óÀÇ °úÁ¦¿¡ ´ëÇÑ ¿ì·Á
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡Àû
    • °æÁ¦
    • »ç±³
    • ±â¼úÀû
    • ¹ý·ü»ó
    • ȯ°æ

Á¦6Àå ÀÚµ¿ ÁÖ»ç±â ½ÃÀå : ÀûÀÀÁõº°

  • °¨¿°Áõ
  • ¿°Áõ¼º Áúȯ/ÀÚ°¡¸é¿ªÁúȯ

Á¦7Àå ÀÚµ¿ ÁÖ»ç±â ½ÃÀå : ¿ëµµº°

  • äÇ÷
  • ¾à¹°Àü´Þ
  • ¿¹¹æÁ¢Á¾

Á¦8Àå ÀÚµ¿ ÁÖ»ç±â ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°

  • ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC)
  • Áø´Ü ½ÇÇè½Ç
  • º´¿ø

Á¦9Àå ¾Æ¸Þ¸®Ä«ÀÇ ÀÚµ¿ÁÖ»ç±â ½ÃÀå

  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦10Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ÀÚµ¿ ÁÖ»ç±â ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦11Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ÀÚµ¿ ÁÖ»ç±â ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
  • ¿µ±¹

Á¦12Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼®(2023³â)
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º(2023³â)
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
  • Àü·« ºÐ¼®°ú Á¦¾È

±â¾÷ ¸ñ·Ï

  • AccuPoint by AdvaCare Pharma
  • Al Shifa Medical Products Co.
  • Apple Syringe
  • Becton Dickinson & Company
  • Duopross Meditech Corp.
  • Hindustan Syringes & Medical Devices Ltd
  • Hunan Pingan Medical Device Technology Co. Ltd. by Winner Medical Co.
  • Injecto A/S
  • Iscon Surgicals Ltd.
  • JMI SYRINGES & MEDICAL DEVICES LTD.
  • Merck KGaA
  • PT Oneject Indonesia
  • Retractable Technologies, Inc.
  • Sanavita Pharmaceuticals GmbH
  • Shandong Zhushi Pharmaceutical Group Co.Ltd.
  • Shanghai Kohope Medical Devices Co. Ltd.
  • Shenzhen Medis Medical
  • Terumo Corporation
BJH 24.12.16

The Auto-disable Syringes Market was valued at USD 23.28 billion in 2023, expected to reach USD 25.94 billion in 2024, and is projected to grow at a CAGR of 11.54%, to USD 50.01 billion by 2030.

Auto-disable syringes are specialized medical devices designed to prevent re-use, thus significantly reducing the risk of spreading infectious diseases through unclean needles. They automatically lock or disable after a single use, aligning with global health safety standards. The necessity for these syringes is driven by the need for safe injection practices, especially in developing regions where infectious diseases like HIV and hepatitis are prevalent. These syringes are widely applied in immunization programs, drug administration, and medical interventions in hospitals and clinics. The end-use scope spans across healthcare facilities, public health organizations, and vaccination campaigns globally. Growing government initiatives and increasing healthcare expenditure are significant growth factors in this market. Additionally, the ongoing COVID-19 pandemic has heightened the demand for secure and efficient vaccination methods, presenting a pivotal opportunity for auto-disable syringe manufacturers to expand their market footprint. Reinforced by technology advancements, these syringes offer potential for innovation such as integrating digital tracking systems for vaccination management and increased production efficiency through automation. However, market growth faces challenges like high production costs, especially in low-resource settings, and the need for spreading awareness and training healthcare workers about these devices. Regional disparities in health infrastructure further complicate market penetration. The industry's nature is intensely competitive and regulated, with numerous players focusing on product differentiation and adherence to stringent health guidelines. Companies can target innovation by exploring biodegradable materials to align with environmental concerns and developing cost-effective manufacturing techniques. Expanding partnerships with government bodies and NGOs for widespread distribution, especially in under-served areas, also represents a strategic opportunity. To maintain competitiveness and growth, businesses should focus on technological upgrades and expanding their reach in emerging markets with increasing healthcare needs.

KEY MARKET STATISTICS
Base Year [2023] USD 23.28 billion
Estimated Year [2024] USD 25.94 billion
Forecast Year [2030] USD 50.01 billion
CAGR (%) 11.54%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Auto-disable Syringes Market

The Auto-disable Syringes Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising incidence of needle stick injuries and cross infection
    • Significant preference of healthcare organizations towards the use of auto-disable syringes
    • Increasing demand for immunization coverage
  • Market Restraints
    • High cost of procurement and raw material
  • Market Opportunities
    • Increasing scope in mass application campaign
    • Ongoing advancements in auto-disable syringes
  • Market Challenges
    • Concern regarding unsafe injection practices and logistic challenges

Porter's Five Forces: A Strategic Tool for Navigating the Auto-disable Syringes Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Auto-disable Syringes Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Auto-disable Syringes Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Auto-disable Syringes Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Auto-disable Syringes Market

A detailed market share analysis in the Auto-disable Syringes Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Auto-disable Syringes Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Auto-disable Syringes Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Auto-disable Syringes Market

A strategic analysis of the Auto-disable Syringes Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Auto-disable Syringes Market, highlighting leading vendors and their innovative profiles. These include AccuPoint by AdvaCare Pharma, Al Shifa Medical Products Co., Apple Syringe, Becton Dickinson & Company, Duopross Meditech Corp., Hindustan Syringes & Medical Devices Ltd, Hunan Pingan Medical Device Technology Co., Ltd. by Winner Medical Co., Injecto A/S, Iscon Surgicals Ltd., JMI SYRINGES & MEDICAL DEVICES LTD., Merck KGaA, PT Oneject Indonesia, Retractable Technologies, Inc., Sanavita Pharmaceuticals GmbH, Shandong Zhushi Pharmaceutical Group Co.,Ltd., Shanghai Kohope Medical Devices Co., Ltd., Shenzhen Medis Medical, and Terumo Corporation.

Market Segmentation & Coverage

This research report categorizes the Auto-disable Syringes Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Indication, market is studied across Infectious Diseases and Inflammatory/Auto-Immune Diseases.
  • Based on Application, market is studied across Blood Collection, Drug Delivery, and Vaccination.
  • Based on End-User, market is studied across Ambulatory Surgical Centers, Diagnostic Laboratories, and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidence of needle stick injuries and cross infection
      • 5.1.1.2. Significant preference of healthcare organizations towards the use of auto-disable syringes
      • 5.1.1.3. Increasing demand for immunization coverage
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of procurement and raw material
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing scope in mass application campaign
      • 5.1.3.2. Ongoing advancements in auto-disable syringes
    • 5.1.4. Challenges
      • 5.1.4.1. Concern regarding unsafe injection practices and logistic challenges
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Auto-disable Syringes Market, by Indication

  • 6.1. Introduction
  • 6.2. Infectious Diseases
  • 6.3. Inflammatory/Auto-Immune Diseases

7. Auto-disable Syringes Market, by Application

  • 7.1. Introduction
  • 7.2. Blood Collection
  • 7.3. Drug Delivery
  • 7.4. Vaccination

8. Auto-disable Syringes Market, by End-User

  • 8.1. Introduction
  • 8.2. Ambulatory Surgical Centers
  • 8.3. Diagnostic Laboratories
  • 8.4. Hospitals

9. Americas Auto-disable Syringes Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Auto-disable Syringes Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Auto-disable Syringes Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AccuPoint by AdvaCare Pharma
  • 2. Al Shifa Medical Products Co.
  • 3. Apple Syringe
  • 4. Becton Dickinson & Company
  • 5. Duopross Meditech Corp.
  • 6. Hindustan Syringes & Medical Devices Ltd
  • 7. Hunan Pingan Medical Device Technology Co., Ltd. by Winner Medical Co.
  • 8. Injecto A/S
  • 9. Iscon Surgicals Ltd.
  • 10. JMI SYRINGES & MEDICAL DEVICES LTD.
  • 11. Merck KGaA
  • 12. PT Oneject Indonesia
  • 13. Retractable Technologies, Inc.
  • 14. Sanavita Pharmaceuticals GmbH
  • 15. Shandong Zhushi Pharmaceutical Group Co.,Ltd.
  • 16. Shanghai Kohope Medical Devices Co., Ltd.
  • 17. Shenzhen Medis Medical
  • 18. Terumo Corporation
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦